STOCKS TELEGRAPH

Tag: ATOS

  • Atossa Therapeutics (ATOS) Stock Shows Little Substance

    Atossa Therapeutics (NASDAQ: ATOS) is an early-stage biopharmaceutical that is slowly making progress with a Covid-19-related treatment. ATOS stock has been declining, given that investors have little to latch onto at the present moment.

    Bleak Financial Outlook for ATOS

    Atossa Therapeutics (ATOS) has not had a good year in the stock market, with ATOS stock price decline of over 75% seen in the last 12 months alone. This lack of confidence by market participants comes as a direct result of poor fundamentals, and little substance to hold on to that would warrant investing one’s capital in. Its EPS of -$0.05 marginally beat the analyst consensus of -$0.06. Moreover, its operating expenses saw a reduction from $7,000 to $6,595 on a year-on-year basis. Its cash holdings have decreased since the prior quarter from $131,100 to $125,500. This clearly points to financing challenges for large-scale drug development.

    Atossa Therapeutics Pipeline and Progress

    Financials, at this point of the company’s lifecycle, do not reflect the inherent value it holds, which is typical of an early-stage bio-pharmaceutical. The company has initiated a number of procedures in the development process of its AT-H201 drug candidate, after the completion of parts B and C of its phase 1/2a clinical trial. Although this stage of the development process is far too early for an opinion to be formed about the drug’s viability, it is progress nonetheless. To add, Atossa also entered into an agreement with a US venture capital firm that will assist the company in relation to operations, personnel, and intellectual property.

    Conclusion

    At present, ATOS stock has little substance going for it, the result of which the market does not have a reason to be confident about its prospects. However, progress is slow, which is better than its affairs being at a complete standstill.

  • Atossa Therapeutics, Inc. (ATOS) stock is declining in Pre-Market today: Why is it so?

    Atossa Therapeutics, Inc. (ATOS) stock is declining in Pre-Market today: Why is it so?

    Shares of the Atossa Therapeutics, Inc. (ATOS) stock were declining in the pre-market trading session today on July 20, 2021, after dropping as much as 13.33% at the previous closing. The ATOS stock price saw a drop of 0.51% to reach $3.88 a share and the trading volume was 24,759,902 as of this writing. Let’s understand why ATOS stock is bearish today.

    What’s Happening?

    Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery and development of medicines for oncology and infectious diseases. There seems to be no news related to Atossa Therapeutics in today’s date to justify the bearish sentiment. No press release or announcement has been made to support the declining per share price of the ATOS stock. For now,it is better to look at some recent events of ATOS stock.

    Atossa fight against Covid-19:

    Though many western countries have made significant progress in vaccinating their population, still Covid-19 is the major health concern due to its evolving variants that are more deadly. Atossa is developing AT-H201 in order to treat patients suffering from moderate covid-19. Attosa is now planning to treat a group of 60 mixed patients that are either recovered or moderately ill hospitalized covid-19 patients in a phase ½a placebo-controlled study by utilizing the combination of blood thinner Heparin and the anti-inflammatory N-acetylcysteine, with AT-H201.

    The Analyst Opinion:

    Maxim analyst Jason McCarthy considered the combination of N-acetylcysteine and Heparin as “intriguing”. McCarthy thinks that the AT-H201 is the only reason that makes ATOS stock more attractive as far as investment in stocks is concerned. He rated the ATOS stock “buy” and set a $7 target price. The ATOS stock is weighed by only two analysts, and both rated the stock “ buy”.

    Performance in June:

    ATOS stock had made significant progress in June 2021 as it became part of Russell 2000 and Russell 3000 indexes. Moreover, the Swedish Medical Product Agency (MPA) approved the commencement of  Endoxifen’s second phase clinical trial study. Endoxifen is used to treat the mammographic breast density (MBD) that is affecting 10 million women in the U.S alone.

    Wrap Up:

    The ATOS stock is declining in the stock market without any obvious reason. Such rises and falls don’t affect the long-term investors who mainly focus on stock’s overall growth and developments.

  • Atossa Therapeutics Inc. (ATOS) stock surged in the premarket trading session; here’s why

    Atossa Therapeutics Inc. (ATOS) stock surged in the premarket trading session; here’s why

    In the premarket trading session, at last check, Atossa Therapeutics Inc. (ATOS) stock had surged by 2.55% to $6.04. ATOS’s stock previously closed the session gaining 10.09% to $5.89. The ATOS stock volume traded 14.72 million shares. In the past week, ATOS shares have moved up by 27.49%. In the past three and six months, the ATOS stock has jumped up by 135.60%, and 584.72% respectively. Furthermore, Atossa therapeutics Inc. is currently valued in the market at $711.65 million and has 120.82 million outstanding shares.

    Here’s what you need to know about Atossa Therapeutics Inc.

    Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the developing and designing of unique innovative treatments and medicines for the unmet needs of the health market. The company specifically focuses on the platform of development and design of medicines for the areas of oncology and infectious disease.

    The company has created programs to fight breast cancers, improve lung functions and has therapy programs as well for the treatment of cancers. The lead candidate program is known as Endoxifen for breast cancer treatment which is in Phase II of clinical trials and is a metabolite of tamoxifen. AT-H201 and AT-301 are proprietary drugs used for the treatment and recovery of lung function in COVID19 patients. ATOS stock also participates and supports research for treatments like potential treatment of breast cancer through cytokine-coated nanoparticles in partnership with Dana-Farber Cancer Institute Inc. Furthermore, the company was previously known as Atossa Genetics Inc up till January 2020 and is founded in 2008. The Atossa headquarters is in Seattle Washington.

    How has Atossa’s operations been doing lately?

    The month of June has been very progressive and successful for ATOS stock and Atossa’s clinical study operations. On 16th June 2021, the company was announced to be part of the Russell 2000 and Russell 3000 Indexes. Atossa is primarily focusing on Breast cancer and COVID19-related treatments. There is a preliminary list of additions that were posted on 4th and 14th June 2021, informing that the official integration will be concluded on 2021 Russell Indexes’ annual reconstitution. The implementation will be effective after US market opens on June 28, 2021.

    On 11th June 2021, ATOS stock received approval from the Swedish Medical Product Agency (MPA) which encourages the initiation of Endoxifen’s second phase clinical trial study. Endoxifen will be used for the treatment and reduction of mammographic breast density (MBD) which is affecting more than 10 million women in the US and scattered across the globe. Increased mammographic breast density results in the difficulty of detecting cancer and increases the development of breast cancer risk.

    Furthermore, Atossa Therapeutics announced the final data of the phase 2 study of oral Endoxifen. This study was used to test the efficacy and safety of the administration of the dose between the time of diagnosis of breast cancer and surgery. The primary endpoint met result showed Ki-67 reduction by an average of 25.6% and has shown clinically meaningful results because these statistics according to to other studies showed a result of improved survival rate.

  • Atossa Therapeutics, Inc. (ATOS) stock up over 6%: Let’s find out why.

    Atossa Therapeutics, Inc. (ATOS) stock up over 6%: Let’s find out why.

    Shares of Atossa Therapeutics, Inc. (ATOS) stock continued the uptrend in today’s market on May 3, 2021, after gaining 0.43% at the previous closing. ATOS stock price saw a surge of 6.01% a share to reach $2.47 a share as of this writing. Atossa CEO Dr. Steven Quay’s participation in a panel discussion at Cello Health’s Cancer Progress Virtual Conference on May 6, 2021, is the only recent news announced by the Atossa stock on April 30, 2021. Let’s discuss more of it.

    What’s happening?

    Atossa Therapeutics, Inc being a pharmaceutical company engages in the discovery and development of medicines related to oncology and infectious diseases. Individuals are eyeing the upcoming panel discussion this week which will last for three days. Many speakers of reputed venture investment funds will attend the conference.

    Previous Development:

    ATOS stock on April 08, 2021, did announce the beginning of treatment of ovarian cancer patient with Atossa’s proprietary oral Endoxifen following the approval of expanded access by the U.S.A Food & Drug Administration for Endoxifen in the “Safe to Proceed” letter. Dr. Barbara Goff, Surgeon-in-Chief treated the patient at the University of Washington Medical Center. The use of Enodxifen was restricted only to that patient and the initial testing showed exceptional results of tumor response after the combination of Endoxifen and alpelisib.

    Financial View of ATOS stock:

    • ATOS stock announced its financial results for the fiscal year 2020 according to which Atossa stock had no source of sustainable revenue and no associated cost of revenue at the end of the year 2020.
    • ATOS stock reported operating expenses of $14,607,000 for the year 2020 which represents a 15% decrease as compared to the operating expenses of 2019.
    • Research and development expenses for ATOS stock were reduced by 1% as compared to 2019 to drop at $6,608,000.Stock-based compensation of $2,214,000 was mainly responsible for this decrease.
    • General and administrative expenses for ATOS stock were totaled $7,999,000 for 2020 representing a decrease of 25% as compared to 2019. The main reason for this decrease was Stock-based compensation of roughly $3,610,000.
    • ATOS stock reported cash, cash equivalents, and restricted cash of $39.7 million at the end of the year 2020.

    Conclusion:

    Things are going well for ATOS stock as far as market sentiment is concerned and the upcoming conference discussed above will further decide the future of the ATOS stock.

  • 24 stocks making the biggest moves premarket today

    24 stocks making the biggest moves premarket today

    ‎Bionano Genomics Inc. (BNGO) stock soared 55.84% to $4.8 in the pre-‎market trading. The company recently granted 180-day extension by Nasdaq to regain ‎compliance with bid price rule. The most recent rating by Ladenburg Thalmann, on September ‎‎24, 2020, is a Buy.‎

    ‎Jaguar Health Inc. (JAGX) grew over 14.11% at $0.93 in pre-market trading ‎today.‎

    ‎Castor Maritime Inc. (NASDAQ: CTRM) shares are trading up 5.41% at $0.195 ‎at the time of writing after revealing the pricing of $18.0 million registered direct offering. ‎Company’s 52-week ranged between $0.11 to $2.60.‎

    ‎Bit Digital Inc. (BTBT), a Software – Application company, rose about 18.3% at ‎‎$25.92 ‎in pre-market trading Monday.‎

    ‎Canaan Inc. (CAN) stock moved up 18.72 percent to $7.04 in the pre-market ‎trading.‎

    ‎Ebang International Holdings Inc. (EBON) stock soared 25.7% to $7.63 in the ‎pre-market trading after declared that the Company expects to commence public testing of its ‎cryptocurrency exchange and officially launch the exchange in the first quarter of 2021.‎

    ‎Riot Blockchain Inc. (NASDAQ: RIOT) shares are trading up 7.18% at $18.21 ‎at the time of writing. Company’s 52-week ranged between $0.51 to $18.16.‎

    ‎Marathon Patent Group Inc. (MARA) stock moved up 10.92 percent to $11.58 ‎in the pre-market trading following the declaration from the firm that that it has successfully ‎completed its $200 million shelf offering by utilizing its at-the-market (ATM) facility. ‎

    ‎Seanergy Maritime Holdings Corp. (SHIP) lost over -2.7% at $0.5231 in pre-‎market trading Monday January 04, 2021.‎

    ‎Li Auto Inc. (LI) gained over 4.68% at $30.18 in pre-market ‎trading ‎Monday ‎January ‎‎04, 2021 after reporting that the Company delivered 6,126 Li ONEs in ‎December ‎‎2020, ‎representing an ‎increase of 31.9% month-over-month and 529.6% year-over-‎year. ‎

    ‎Gevo Inc. (GEVO) grew over 10.12% at $4.68 in pre-market trading today.‎

    Before the trading started on January 04, 2021, Kinross Gold Corporation ‎‎(KGC) is up 4.9% to reach $7.7. It has been trading in a 52-week range of $2.72 to ‎‎$10.31.‎

    ‎Ocugen Inc. (OCGN), a Biotechnology company, rose about 125.14% at $4.12 ‎in pre-‎‎‎‎market trading Monday.‎

    ‎Color Star Technology Co. Ltd. (CSCW) stock plunged -9.79% to $0.6351 in the ‎pre-market trading. The company recently revealed strategic partnership with two UAE ‎companies. ‎

    ‎Avinger Inc. (AVGR) is up more than 8.16% at $0.476 in pre-market hours ‎Monday ‎January 04, 2021. The stock had dropped over -6.86% to $0.44 in the last trading ‎session.‎

    ‎Harmony Gold Mining Company Limited (HMY) stock soared 9.19% to $5.11 ‎in ‎the ‎pre-market trading. The most recent rating by JP Morgan, on February 21, 2019, is an ‎Overweight.‎

    ‎PEDEVCO Corp. (PED) is down more than -5.3% at $1.43 in pre-‎‎market ‎hours ‎Monday January 04, 2021. The stock had jumped over 20.80% to $1.51 in the last ‎trading ‎session.‎

    ‎Orbital Energy Group Inc. (NASDAQ: OEG) shares are trading up 5.02% at ‎‎$2.3 at ‎the ‎time of writing after pricing $10 million registered direct offering. Company’s 52-‎week ranged ‎between ‎‎$0.45 to $2.80.‎

    ‎Aethlon Medical Inc. (AEMD) is down more than -6.88% at $2.3 in pre-‎market ‎hours ‎Monday January 04, 2021. The stock had jumped over 19.32% to $2.47 in the last ‎trading session.‎

    Before the trading started on January 04, 2021, Invitae Corporation (NVTA) is ‎up 4.31% to reach $43.61. The company recently revealed that Sean George, co-founder and ‎chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan Healthcare ‎Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. It has been ‎trading in a 52-week range of $7.41 to $61.59.‎

    ‎Hall of Fame Resort & Entertainment Company (HOFV), a ‎Entertainment ‎company, ‎rose about 31.71% at $1.62 in pre-market trading Monday.‎

    ‎T2 Biosystems Inc. (TTOO) is down more than -3.23% at $1.2 in pre-‎market ‎hours ‎Monday January 04, 2021. The stock had dropped over -0.80% to $1.24 in the last ‎trading session.‎

    ‎Clearside Biomedical Inc. (NASDAQ: CLSD) shares are trading up 7.66% ‎at ‎‎$2.95 ‎at ‎the time of writing. Company’s 52-week ranged between $1.10 to $4.13. Analysts ‎have ‎a ‎consensus ‎price target of $8.‎

    ‎Teligent Inc. (NASDAQ: TLGT) shares are trading down -5.13% at $0.7115 at ‎the time of writing after declaring its financial results for the third quarter ended September ‎‎30, 2020. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price ‎target of $2.‎

  • 26 stocks trending in pre-market

    ‎Bionano Genomics Inc. (BNGO) stock soared 13.81% to $2.39 in the pre-‎market ‎trading following an announcement from the firm that Nasdaq has granted the Company an ‎additional ‎‎180-day compliance period, or until June 28, 2021. The most recent rating by Ladenburg ‎Thalmann, on ‎September 24, 2020, is a Buy. ‎

    Before the trading started on December 31, 2020, fuboTV Inc. (FUBO) is down -‎‎‎2.43% to reach $32.5. It has been trading in a 52-week range of $5.00 to $62.29.‎

    ‎Guardion Health Sciences Inc. (NASDAQ: GHSI) shares are trading down -10.77% ‎at ‎‎$0.5247 at the time of writing. The firm lately revealed the appointment of Bret Scholtes as ‎its ‎President and Chief Executive Officer, and as a member of the Board of Directors. Company’s 52-‎week ‎ranged between $0.17 to $0.74.‎

    ‎Nxt-ID Inc. (NXTD) stock soared 7.1% to $1.81 in the pre-market trading. ‎The ‎most ‎recent rating by Maxim Group, on November 20, 2017, is a Buy.‎

    ‎Castor Maritime Inc. (CTRM) grew over 41.75% at $0.33 in pre-market trading ‎today ‎after receiving 180-day extension from Nasdaq to meet Nasdaq minimum bid price rule. ‎

    ‎Net Element Inc. (NASDAQ: NETE) shares are trading down -5.21% at $15.45 at ‎the ‎time of writing. Company’s 52-week ranged between $1.47 to $20.08. ‎

    ‎Sundial Growers Inc. (SNDL) stock moved down -1.36 percent to $0.4784 in the pre-‎‎market trading following the declaration from the company that it has closed the acquisition of ‎a ‎special purpose vehicle. ‎

    ‎Professional Diversity Network Inc. (IPDN) gained over 14.96% at $3.15 in pre-‎‎market trading Thursday December 31, 2020 after the firm revealed its partnership with ‎Phala ‎Network.‎

    ‎Marathon Patent Group Inc. (MARA) is up more than 7.63% at $11.71 in pre-‎market ‎hours Thursday December 31, 2020. The company recently revealed that it has entered into a ‎contract ‎with Bitmain to purchase 70,000 Antminer S-19 ASIC miners. The stock had dropped over -‎‎7.48% to ‎‎$10.88 in the last trading session.‎

    ‎Riot Blockchain Inc. (RIOT), a Software – Application company, rose about ‎‎4.92% ‎at ‎‎$18.11 in pre-market trading Thursday.‎

    ‎Nano Dimension Ltd. (NNDM) stock moved up 2.09 percent to $9.75 in the pre-‎‎market trading after closing $250 million registered direct offering.‎

    ‎AIkido Pharma Inc. (AIKI) gained over 33.72% at $1.15 in pre-‎‎market ‎trading ‎Thursday December 31, 2020.‎

    ‎Color Star Technology Co. Ltd. (NASDAQ: CSCW) shares are trading down -4.38% ‎at ‎‎$0.8032 at the time of writing after declaring strategic partnership with two UAE ‎companies. ‎Company’s 52-week ranged between $0.31 to $2.06.‎

    ‎IMAC Holdings Inc. (IMAC) stock moved down -4.08 percent to $1.41 in the pre-‎‎market trading after reporting completion of first infusion of Stem Cells in clinical study for ‎the ‎treatment of Bradykinesia due to Parkinson’s disease.‎

    ‎Ampio Pharmaceuticals Inc. (AMPE) stock soared 12.84% to $1.67 in the pre-‎market ‎trading. The firm recently revealed that it has received guidance from the U.S Food & ‎Drug ‎Administration regarding the impact of COVID-19 on its Phase III clinical trial for osteoarthritis of ‎the ‎knee. The most recent rating by ROTH Capital, on December 19, 2019, is a Buy.‎

    ‎Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares are trading up 5.76% ‎at ‎‎$49.4 at the time of writing after the company announced that it would develop a therapeutic spray ‎as ‎a candidate to treat the hereditary lung and digestive-system disease cystic fibrosis. Company’s 52-‎‎week ranged between $8.51 to $129.71. Analysts have a consensus price target of $69. ‎

    Before the trading started on December 31, 2020, Baidu Inc. (BIDU) is up ‎‎3.53% ‎to ‎reach $227.38. It has been trading in a 52-week range of $82.00 to $202.79.‎

    ‎Greenpro Capital Corp. (GRNQ) is up more than 3.11% at $1.99 in pre-market ‎hours ‎Thursday December 31, 2020. The company lately revealed that it intends to set up a Bitcoin ‎‎($BTC) ‎Fund for investment. The stock had jumped over 3.76% to $1.93 in the last trading session.‎

    ‎Onconova Therapeutics Inc. (ONTX) is down more than -3.79% at $0.49 in pre-‎‎market hours Thursday December 31, 2020. The stock had jumped over 18.88% to $0.51 in the ‎last ‎trading session.‎

    ‎JinkoSolar Holding Co. Ltd. (JKS) grew over 2.28% at $65.55 in pre-market ‎trading ‎today. The firm recently revealed annual general meeting 2020 ‎results.‎

    ‎Tonix Pharmaceuticals Holding Corp. (TNXP) lost over -2.76% at $0.6632 in pre-‎‎market trading Thursday December 31, 2020.‎

    ‎Osmotica Pharmaceuticals plc (OSMT) stock moved down -2.13 percent to $4.14 ‎in ‎the pre-market trading after declaring that the U.S. Food and Drug Administration (FDA) has ‎declined ‎to approve one of its products. ‎

    ‎Cinedigm Corp. (CIDM) is down more than -0.69% at $0.62 in pre-‎market ‎hours ‎Thursday December 31, 2020. The stock had dropped over -9.51% to $0.62 in the last ‎trading ‎session.‎

    ‎Novan Inc. (NOVN), a Biotechnology company, dropped about -7.71% at $0.969 ‎in ‎pre-market trading Thursday.‎

    Before the trading started on December 31, 2020, Canaan Inc. (CAN) is ‎up ‎‎25.57% ‎to ‎reach $5.5. It has been trading in a 52-week range of $1.76 to $8.69.‎

    ‎500.com Limited (WBAI) gained over 5.12% at $8.0 in pre-market trading ‎Thursday ‎December 31, 2020. The company recently declared that Mr. Zhaofu Tian has resigned as ‎Chief ‎Technology Officer of the Company due to personal reasons.‎

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.

  • 29 Stocks Taking Bigger Strides in Pre Market Session

    29 Stocks Taking Bigger Strides in Pre Market Session

    Aethlon Medical Inc. (NASDAQ: AEMD) shares are trading down -7.08% at $2.1 at the time of writing after reporting First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer. Company’s 52-week ranged between $0.76 to $4.34.

    Nxt-ID Inc. (NXTD) stock soared 41.77% to $1.31 in the pre-market trading. The most recent rating by Maxim Group, on November 20, 2017, is a Buy.

    Atossa Therapeutics Inc. (ATOS) gained over 9.38% at $1.05 in pre-market trading Thursday December 17, 2020.

    iQIYI Inc. (IQ) stock moved up 1.8 percent to $18.43 in the pre-market trading following the pricing of its offering of US$800 Million 4.00% convertible senior notes due 2026 and its offering of 40,000,000 American Depositary Shares.

    Naked Brand Group Limited (NAKD), a Apparel Manufacturing company, dropped about -2.44% at $0.1561 in pre-market trading Thursday.

    Diginex Limited (EQOS) is up more than 8.02% at $10.5 in pre-market hours Thursday December 17, 2020. The stock had jumped over 35.75% to $9.72 in the last trading session.

    Riot Blockchain Inc. (RIOT) gained over 9.67% at $11.8 in pre-market trading Thursday December 17, 2020. The firm recently reported an 8 megawatt (MW) pilot project to assess the potential for higher productivity and lower cost mining opportunities in Texas.

    Marathon Patent Group Inc. (MARA) grew over 19.81% at $9.86 in pre-market trading today.

    Zomedica Corp. (ZOM) is down more than -1.97% at $0.1594 in pre-market hours Thursday December 17, 2020. The stock had dropped over -3.21% to $0.16 in the last trading session.

    Phunware Inc. (NASDAQ: PHUN) shares are trading up 4.85% at $1.02 at the time of writing. Company’s 52-week ranged between $0.54 to $3.00. Analysts have a consensus price target of $4.

    Before the trading started on December 17, 2020, Genius Brands International Inc. (GNUS) is down -2.37% to reach $1.65. It has been trading in a 52-week range of $0.05 to $11.73.

    Before the trading started on December 17, 2020, Jaguar Health Inc. (JAGX) is down -2.52% to reach $0.4099. It has been trading in a 52-week range of $0.19 to $1.08.

    Kinross Gold Corporation (KGC) grew over 2.2% at $7.43 in pre-market trading today.

    Neovasc Inc. (NVCN) stock plunged -6.25% to $0.9 in the pre-market trading after declaring publication of peer-reviewed article in Euro Intervention. The most recent rating by Canaccord Genuity, on January 19, 2018, is a Buy.

    Transocean Ltd. (RIG) stock moved up 3.31 percent to $2.5 in the pre-market trading.

    Moderna Inc. (MRNA), a Biotechnology company, dropped about -1.66% at $134.75 in pre-market trading Thursday. The firm recently revealed that the it concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19

    Yamana Gold Inc. (AUY) stock soared 2.13% to $5.75 in the pre-market trading. The most recent rating by BMO Capital Markets, on November 16, 2020, is an Outperform.

    BioLineRx Ltd. (NASDAQ: BLRX) shares are trading up 3.15% at $2.95 at the time of writing after revealing final results from Phase 2 a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC). Company’s 52-week ranged between $1.06 to $3.72. Analysts have a consensus price target of $3.

    MicroVision Inc. (MVIS) tumbled over -0.5% at $3.99 in pre-market trading today.

    DAVIDsTEA Inc. (DTEA), a Packaged Foods company, dropped about -2.12% at $2.31 in pre-market trading Thursday following release its third quarter results for the period ended October 31, 2020.

    Bit Digital Inc. (BTBT) gained over 18.02% at $5.96 in pre-market trading Thursday December 17, 2020.

    BioCardia Inc. (BCDA) is up more than 3.45% at $6.0 in pre-market hours Thursday December 17, 2020 after reporting $10.5 million registered direct offering priced at-the-market under Nasdaq rules. The stock had dropped over -13.43% to $5.80 in the last trading session.

    Before the trading started on December 17, 2020, Canaan Inc. (CAN) is up 15.79% to reach $4.4. It has been trading in a 52-week range of $1.76 to $8.69.

    TransEnterix Inc. (TRXC) stock plunged -0.39% to $0.58 in the pre-market trading. The firm today revealed that Southern Surgical Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System. The most recent rating by RBC Capital Mkts, on August 08, 2019, is a Sector perform.

    Xunlei Limited (NASDAQ: XNET) shares are trading up 7.89% at $3.28 at the time of writing. Company’s 52-week ranged between $2.38 to $5.94.

    Coeur Mining Inc. (CDE) grew over 4.09% at $10.7 in pre-market trading today after revealing details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project.

    Hecla Mining Company (HL) stock moved up 2.41 percent to $5.96 in the pre-market trading.

    9 Meters Biopharma Inc. (NMTR), a Biotechnology company, rose about 19.21% at $0.9 in pre-market trading Thursday after declaring closing of offering of common stock.

    First Majestic Silver Corp. (AG) stock moved up 1.74 percent to $12.3 in the pre-market trading.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.